FETUB inhibits cholangiocarcinoma progression and enhances cisplatin sensitivity through promoting YAP1 ubiquitination and degradation
Cholangiocarcinoma (CCA) remains a highly lethal malignancy, and the emergence of cisplatin resistance represents a major constraint on systemic treatment. Fetuin B (FETUB), a liver-derived glycoprotein, has not been well characterized in CCA. The expression and clinical significance of FETUB were evaluated using public datasets and an independent CCA cohort. Gain- and loss-of-function experiments were performed to assess the effects of FETUB on CCA cell proliferation, migration and cisplatin sensitivity. Proteomic analysis was used to identify potential downstream pathways. The molecular relationship between FETUB and YAP1 was investigated using co-immunoprecipitation and ubiquitination assays. Xenograft models and clinical specimens were further used for functional and clinical validation. FETUB was significantly downregulated in CCA and reduced FETUB expression was linked to more aggressive clinicopathological characteristics and inferior survival. FETUB overexpression inhibited CCA cell proliferation and migration and increased cisplatin sensitivity, whereas FETUB depletion produced the opposite effects. Mechanistically, FETUB interacted with YAP1 and reduced YAP1 protein stability. FETUB promoted YAP1 ubiquitination and proteasomal degradation, and mutation of K90 markedly attenuated the observed ubiquitination signal. Pharmacological inhibition of YAP1 partially restored cisplatin sensitivity following FETUB depletion and suppressed tumor growth in vivo. Analysis of patient specimens revealed an inverse relationship between FETUB and YAP1 abundance, with the low-FETUB/high-YAP1 subgroup showing the poorest survival. FETUB acts as a tumor suppressor in CCA and favors cisplatin responsiveness through enhanced ubiquitination and proteasomal turnover of YAP1. The FETUB/YAP1 axis may therefore have value for risk stratification and provide a molecular basis for therapeutic strategies aimed at improving cisplatin sensitivity in CCA.
Authors
- 周泉波
- Jiangyuan Huang (ORCID: https://orcid.org/0009-0003-8838-268X)
- 侯宝华
- Deyi Huang
- 王仪春
- Hanyang Guan (ORCID: https://orcid.org/0009-0002-8853-6151)
- Jiayu Yang (ORCID: https://orcid.org/0009-0009-5406-9218)
- Pengcong Zheng
Institutions
- Guangdong Medical College (CN)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- Biology Direct
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1186/s13062-026-01059-w
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00